Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta-analysis

Liver Transplantation

Volumn 18, Issue 1, 2012, Pages 62-69

  Liang, Wenhua ^a   Wang, Dongping ^a   Ling, Xiaoting ^a   Allen Kao, Andrew ^b   Kong, Yuan ^a   Shang, Yushu ^a   Guo, Zhiyong ^a   He, Xiaoshun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PUBLISHING; RISK REDUCTION; SENSITIVITY ANALYSIS; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SIROLIMUS; SURVIVAL RATE;

EID: 84255162255     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22441     Document Type: Article

References (29)

1. Botha JF, Langnas AN,. Liver transplantation for hepatocellular carcinoma: an update. J Natl Compr Canc Netw 2006; 4: 762-767. (Pubitemid 44412393)
2. Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, et al. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria. Transplant Proc 2008; 40: 3548-3553.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699. (Pubitemid 26079803)
4. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW,. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008; 143: 182-188. (Pubitemid 351281631)
5. Freise CE, Ferrell L, Liu T, Ascher NL, Roberts JP,. Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma. Transplantation 1999; 67: 510-513. (Pubitemid 29114209)
6. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
7. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008; 248: 857-862.
8. Panwalkar A, Verstovsek S, Giles FJ,. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100: 657-666. (Pubitemid 38176841)
9. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-135. (Pubitemid 34155123)
10. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M,. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572. (Pubitemid 34568667)
11. Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311. (Pubitemid 39406087)
12. McAlister VC, Peltekian KM, Malatjalian DA, Colohan S, MacDonald S, Bitter-Suermann H, MacDonald AS,. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701-708. (Pubitemid 32771469)
13. Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I,. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343-351. (Pubitemid 32331539)
14. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168. (Pubitemid 46743675)
15. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, et al. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190.
16. Hüser N, Michalski CW, Erkan M, Schuster T, Rosenberg R, Kleeff J, Friess H,. Systematic review and meta-analysis of the role of defunctioning stoma in low rectal cancer surgery. Ann Surg 2008; 248: 52-60.
17. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Published March 2011. Accessed September 2011.
18. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
19. Begg CB, Mazumdar M,. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
20. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.
21. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231.
22. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638. (Pubitemid 351696274)
23. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842.
24. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-395.
25. de Mattos AM, Olyaei AJ, Bennett WM,. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-346. (Pubitemid 30070861)
26. Alberú J,. Clinical insights for cancer outcomes in renal transplant patients. Transplant Proc 2010; 42 (suppl): S36-S40.
27. Flechner SM, Goldfarb D, Solez K, Modlin CS, Mastroianni B, Savas K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892. (Pubitemid 46682728)
28. Rogers CC, Johnson SR, Mandelbrot DA, Pavlakis M, Horwedel T, Karp SJ, et al. Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. Clin Transplant 2009; 23: 887-896.
29. Shenoy S, Hardinger KL, Crippin J, Desai N, Korenblat K, Lisker-Melman M, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83: 1389-1392. (Pubitemid 46800318)